NCT00448240View on ClinicalTrials.gov

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

PHASE2/PHASE3TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Head and Neck CancerCarcinoma, Squamous Cell

Interventions

DRUG

Erlotinib

loading dose of 300 mg on Day 2 followed by 150 mg daily Days 3 - 17 of each cycle of paclitaxel and cisplatin/carboplatin

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Henry Ford Health System

OTHER